Welcome to our dedicated page for APTARGROUP SEC filings (Ticker: ATR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AptarGroup, Inc.'s SEC filings document operating results, governance matters and capital-structure activity for a NYSE-listed maker of drug delivery and consumer-product dispensing technologies. Form 8-K reports furnish quarterly and annual results, segment commentary for Pharma, Beauty and Closures, shareholder returns and material events tied to the company's operations.
The filing record also includes proxy materials and annual meeting vote results covering director elections, advisory compensation matters and stockholder voting items. Capital disclosures include common stock registered under the Exchange Act, shelf-registration activity and completed debt financing, including the 4.750% Senior Notes due 2031 issued under an indenture.
AptarGroup, Inc. (ATR) filed a Form 144 reporting a proposed sale of 1,167 common shares. The sale is to be handled by Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $161,006.44 and an approximate sale date of 09/05/2025. The shares were acquired on 05/02/2025 through restricted stock vesting under a registered plan and were issued by the issuer as payment for services rendered on 05/02/2025. The filer reports no securities sold in the past three months. The filing includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.